Iovance Biotherapeutics (LTS:0JDK) Total Payout Ratio : 0.93 (As of May. 10, 2025)

View and export this data going back to 2018. Start your Free Trial

What is Iovance Biotherapeutics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Iovance Biotherapeutics's current Total Payout Ratio is 0.93.

Iovance Biotherapeutics Total Payout Ratio Historical Data

The historical data trend for Iovance Biotherapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics Total Payout Ratio Chart

Iovance Biotherapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Payout Ratio

Get a 7-Day Free Trial

2.18

0.59

0.48

1.04

1.07

Iovance Biotherapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Payout Ratio	Get a 7-Day Free Trial															1.75	1.56	0.57	-	1.28

Competitive Comparison of Iovance Biotherapeutics's Total Payout Ratio

For the Biotechnology subindustry, Iovance Biotherapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iovance Biotherapeutics's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Total Payout Ratio falls into.

Save Embed

;

Save Embed

;

Iovance Biotherapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Iovance Biotherapeutics's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	397.304	+	0)	/	-372.177
	=	1.07

Iovance Biotherapeutics's Total Payout Ratio for the quarter that ended in Mar. 2025 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	148.944	+	0)	/	-116.163
	=	1.28

Iovance Biotherapeutics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (LTS:0JDK) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

IOVA:USA 2LB:Germany 2LB:Germany

Address

825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics Headlines

No Headlines